Rat Model Market Size

Rat Model Market Size

Rat Model Market was valued at over USD 1.4 billion in 2021 and is estimated to witness 7.6% CAGR by the end of 2028. Growing consumption of personalized medicine and increasing number of clinical trials is expected to augment the market growth during the estimated timeframe.

To get key market trends

  Download Free Sample

Rat models mimic human disease owing to certain similarities in their pathology to disease conditions that are similar in humans. Under specific conditions, the recurrence and progression of rat diseases are identical to that of humans. The notable anatomical and physiological similarities between rats and humans have encouraged researchers to investigate a broad spectrum of mechanisms and evaluate novel therapies in these research models.
 

For instance, in oncology research, the rat model-based research assists in understanding the genetic basis of cancer and the role of different genes & gene mutations in the development and progression of cancer that further facilitates the development of antineoplastic medications. These models are employed to study diseases such as hypertension, diabetes, Parkinson's disease, Alzheimer's disease, an acquired immunodeficiency syndrome (AIDS), and muscular dystrophy among other diseases. Thus, the similarities between rats and humans increase their acceptance in disease studies, further fuelling the rat model market growth.
 

Rat model can be defined as a non-human and living, a genetic-engineered animal that is used for the scientific research purpose and investigation of human diseases. Also, these rat models are used for the purpose of better understanding of the human disease process without harming an actual human.
 

However, several regulatory bodies are highlighting concerns regarding rat testing that in turn has led to the development of guidelines for optimal rat welfare and usage during biomedical research. The regulatory bodies were established after the pressure from several animal protection organizations and enacted several laws to facilitate the care and usage of laboratory rat testing.
 

Furthermore, animal organizations such as People for The Ethical Treatment of Animals (PETA), Cruelty Free International, and others are opposing the use of rat models in research. Also, this opposition has led to the establishment of animal welfare acts including the Cruelty to Animals Act that aids in the prevention of unnecessary animal pain and suffering. Thus, the growing opposition to the use of rat testing in biomedical research may reduce the usage of rats.
 

The emergence of COVID-19 is an unprecedented public health concern that has positively impacted the rat model market share. The coronavirus outbreak has affected the healthcare industry through financial adversities on the health facilities as well. The healthcare sector was also largely affected by the increasing prevalence of COVID-19 cases. Although, heavy investments in research activities related to COVID-19 and the increased funding towards R&D activities to innovate novel therapeutics have promoted the use of rat testing despite the pandemic.
 

Several pharmaceuticals, biotechnology companies and clinical research organizations revised their R&D spending for clinical trials in comparison to earlier spending, demonstrating the magnitude of disruption caused by the pandemic. While the clinical trials concerning COVID-19 were booming, rapid recovery was observed due to the proliferation of new clinical trial approaches to promote antiviral drug and vaccine development.
 

Furthermore, to minimize the adverse effect of the pandemic, the organizations that operate traditionally have enabled themselves for collaboration opportunities to expand the capability to support hybrid models. These developments helped to continue clinical research & development activities, ensuring the inflow and the use of rat models, further facilitating the rat model market growth.